European Biotechnology Winter 2026
Preview Winter 2026
© @magnific
Radiopharmaceuticals SPECIAL
Publication date: 26 November, 2026
Radiopharmaceuticals The next wave of precision oncology Radiopharmaceuticals and theranostics are opening new possibilities for cancer diagnosis and treatment by combining molecular targeting with radioactive isotopes. From radioligand therapies and targeted alpha emitters to imaging agents that help select patients and guide treatment, the field brings together drug discovery, nuclear medicine and specialist manufacturing. Translating these approaches into wider clinical use requires more than promising molecules: reliable isotope supplies, scalable production, coordinated logistics and access to treatment centers are essential. In its Winter 2026 issue, European Biotechnology will spotlight the companies, technologies and partnerships shaping Europe’s radiopharmaceutical sector, from emerging therapeutictargets to the infrastructure needed to deliver treatments to patients.
Present your expertise Drug developers, isotope producers, CDMOs, CROs, nuclear medicine specialists, equipment suppliers and technology providers will have the opportunity to present their latest products, processes and innovations in this special feature. European Biotechnology reaches decision-makers throughout the European life s ciences sector and, through our official partner SLAS, in the USA. Showcase your expertise to potential customers and partners working across radiopharmaceutical development, manufacturing and clinical delivery.
Examples of topics Radioligand therapies, targeted alpha therapies, beta emitters, theranostics, novel tumor targets, targeting ligands and antibodies, chelator and linker chemistry, isotope production and supply, radiolabeling, process development, GMP manufacturing, automation and hot-cell technology, quality control, radiation protection, dosimetry, molecular imaging, patient selection, clinical trial design, regulatory strategy, specialist logistics and treatment access.
Editorial Deadline 12-11-2026
Booking Deadline 12-11-2026
Publication Date 26-11-2026
Editorial contact:: Joachim Eeckhout Tel.: +49-30-264921-29 joachim.eeckhout@knowb.io
Marketing contact: Oliver Schnell Tel.: +49-30-264921-45 oliver.schnell@knowb.io
Marketing contact: Andreas Macht Tel.: +49-30-264921-54 andreas.macht@knowb.io
Knowbio GmbH I Lessingstr. 12 I 16552 Mühlenbecker Land I www.knowb.io